ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

leuprolide mesylate

Also written as “Leuprolide Mesylate” and “Leuprolide Injectable Emulsion (CAMCEVI®)”.

Its studies are mostly in Prostatic Neoplasms, led by 2 companies.

Drug pageLeuprolide mesylate: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Sep 1, 20143 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Foresee Pharmaceuticals20 open or runningphase 3since Sep 1, 2014Sep 1, 2014none ahead
Changchun GeneScience Pharmaceuticalits history only10 open or runningphase 3since May 11, 2025May 11, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Foresee Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 1, 2014First study: phase 3 study in Prostatic NeoplasmsFirst studyNCT02234115 · 137 enrolled · United States, Austria, Czechia and more
  2. Aug 19, 2017Phase 3 study in Prostatic NeoplasmsNCT03261999 · 144 enrolled · United States, Czechia, Korea, Republic of and more

TargetBeta

GNRHR →read by rule
“Gonadotropin-releasing hormone receptor agonist; Gonadotropin-releasing hormone receptor agonist”ChEMBL 37, by rule

Other programs on GNRHR

ProgramCompanyFurthest phaseStudies
LeuprolideruleTakedaphase 439
triptorelinruleIpsenphase 421
GoserelinruleAstraZenecaphase 414
linzagolixruleKissei Pharmaceuticalphase 314
GnRH Antagonist SHR7280Jiangsu HengRui Medicinephase 310
Gonadotropin-Releasing HormoneruleFerring Pharmaceuticalsphase 35

Studies

All 2 Foresee Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03261999Prostatic Neoplasms · United States, Czechia, Korea, Republic of and more3CompletedNov 19, 2018144
NCT02234115Prostatic Neoplasms · United States, Austria, Czechia and more3CompletedAug 30, 2016137

How it is read

Names in the registry

  • “Leuprolide Mesylate”, 2 entries
  • “Leuprolide Injectable Emulsion (CAMCEVI®)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.